Investigational drug · Phase 3
Intismeran autogene
Also called: V940, mRNA-4157, Intismeran, Individualized neoantigen therapy
Not approved by FDA. In 10 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Cancer, Melanoma, Bladder Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
10
10 still active
All registered trials
11
Any phase or sponsor naming "Intismeran autogene"
First trial start
2019
Jul 18, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Intismeran autogene", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer
- Melanoma
- Bladder Cancer
- Renal Cell Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Squamous Non-small Cell Lung Cancer
- Urinary Bladder Neoplasms
- Non-Muscle Invasive Bladder Neoplasms
- Carcinoma in Situ
- Malignant Melanoma
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Melanoma · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma) · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Intismeran autogene" as an intervention, largest first.
- A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05933577 · 1,089 participants (planned) · Start Jul 19, 2023 · Primary completion Oct 26, 2029
Drug: Intismeran autogene; Pembrolizumab · For: Melanoma
Sites: Springdale, Arkansas; Los Angeles, California; San Francisco, California · 165 sites in all
- A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07513376 · 876 participants (planned) · Start May 4, 2026 · Primary completion Aug 22, 2034
Drug: Intismeran; Pembrolizumab coformulated with berahyaluronidase alfa · For: Non-small Cell Lung Cancer
Sites: Sacramento, California; Aurora, Colorado; New Haven, Connecticut · 129 sites in all
- A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06077760 · 868 participants (planned) · Start Dec 6, 2023 · Primary completion Jun 25, 2030
Drug: Intismeran autogene; Pembrolizumab · For: Non-small Cell Lung Cancer
Sites: Anchorage, Alaska; Tucson, Arizona; Yuma, Arizona · 229 sites in all
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06623422 · 680 participants (planned) · Start Oct 21, 2024 · Primary completion May 16, 2033
Drug: Pembrolizumab; Cisplatin and 5 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Gilbert, Arizona; Tucson, Arizona; Fullerton, California · 247 sites in all
- A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06833073 · 308 participants (planned) · Start Mar 11, 2025 · Primary completion Sep 3, 2031
Drug: Intismeran autogene; BCG · For: Urinary Bladder Neoplasms; Non-Muscle Invasive Bladder Neoplasms; Carcinoma in Situ
Sites: Bakersfield, California; Los Alamitos, California; Los Angeles, California · 89 sites in all
- A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06307431 · 272 participants (planned) · Start Apr 10, 2024 · Primary completion Jan 8, 2028
Drug: Intismeran autogene; Pembrolizumab and 1 more · For: Renal Cell Carcinoma
Sites: Duarte, California; Los Angeles, California; San Francisco, California · 63 sites in all
- A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06305767 · 230 participants (planned) · Start Mar 28, 2024 · Primary completion Apr 23, 2027
Drug: Pembrolizumab; Intismeran autogene and 1 more · For: Bladder Cancer
Sites: Los Angeles, California; Orlando, Florida; Chicago, Illinois · 74 sites in all
- A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07221474 · 180 participants (planned) · Start Dec 12, 2025 · Primary completion Jul 2, 2029
Drug: Intismeran Autogene; Pembrolizumab and 3 more · For: Squamous Non-small Cell Lung Cancer
Sites: Tampa, Florida; Ann Arbor, Michigan; St Louis, Missouri · 56 sites in all
- Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid TumorsActive, not recruiting
ModernaTX, Inc.Moderna (MRNA)
NCT03313778 · 161 participants · Start Aug 14, 2017 · Primary completion Nov 21, 2027
Drug: mRNA-4157; Pembrolizumab and 1 more · For: Solid Tumors
Sites: Los Angeles, California; Washington D.C., District of Columbia; Orlando, Florida · 20 sites in all
- A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06961006 · 160 participants (planned) · Start May 29, 2025 · Primary completion Jul 22, 2028
Drug: Intismeran autogene; Pembrolizumab · For: Malignant Melanoma
Sites: Springdale, Arkansas; San Francisco, California; Hackensack, New Jersey · 38 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma.
Long GV, Khattak MA, Gogas HJ, et al. · N Engl J Med 2026
- Messenger RNA vaccine platforms from molecular optimization to infectious disease and cancer immunotherapy: a narrative review.
Wang Q, Sun Z, Liu H · Transl Cancer Res 2026
- Vaccines for Cancer: A Translational Science Review.
Disis ML, Chun BMN, Dhillon KK, et al. · JAMA 2026
- First mRNA Cancer Vaccine Succeeds in Phase III Trial.
· Cancer Discov 2026
- Emerging immunotherapies in melanoma beyond immune checkpoint inhibitors: Vaccines, intralesional therapies, adoptive cell therapies, and T-cell engagers.
Taglialatela I, Di Corcia L, Boutros A, et al. · Cancer Treat Res Commun 2026
- Biomimetic and personalized nanovaccines in cancer immunotherapy: Design innovations, translational challenges, and future directions.
Xu S, Yang H, Minev B, et al. · J Adv Res 2026
Also in development for Non-small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.